Mixed trend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend up since Jun 4 · above the Ichimoku cloud · RSI 41 · MACD below its signal
| 6.00 | 52-week high | +26.58% |
| 5.14 | Previous month high | +8.44% |
| 5.13 | R3 (classic) | +8.30% |
| 5.06 | R2 (classic) | +6.68% |
| 5.00 | Previous week high | +5.49% |
| 4.98 | Previous day high | +5.06% |
| 4.90 | R1 (classic) | +3.45% |
| 4.83 | Pivot | +1.83% |
| 4.75 | Previous day low | +0.21% |
| 4.74 | Price now | |
| 4.67 | S1 (classic) | −1.41% |
| 4.60 | S2 (classic) | −3.02% |
| 4.44 | S3 (classic) | −6.26% |
| 4.00 | Previous week low | −15.61% |
| 4.00 | Previous month low | −15.61% |
| 3.25 | 52-week low | −31.43% |
None of the 29 investors followed here reported a position in MDRX in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a MDRX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| May 31, 2026 | Felt Bruce C. Jr.Director | — | 42.5K | — |
| May 31, 2026 | Stevens David BDirector | — | 42.5K | — |
| May 31, 2026 | Zierhoffer Carol JDirector | — | 42.5K | — |
| May 31, 2026 | Rodriguez SusanDirector | — | 42.5K | — |
| May 31, 2026 | Silverman Louis EDirector | — | 42.5K | — |
| May 31, 2026 | Sacks Jonathan SDirector and Beneficial Owner of more than 10% of a Class of Security | — | 42.5K | — |
| May 31, 2026 | Greyenbuhl ChristianChief Financial Officer | — | 318.8K | — |
| May 31, 2026 | Stonehill Capital Management L L CBeneficial Owner of more than 10% of a Class of Security | — | 42.5K | — |
| May 31, 2026 | Asar Vinit K.Director | — | 42.5K | — |
| Apr 30, 2026 | Jacobson Eric LGeneral Counsel | — | 75K | — |
| Mar 31, 2026 | Trigg DonaldChief Executive Officer | — | 552.5K | — |
| Mar 31, 2026 | Syed Tehsin MOfficer | — | 221K | — |
| Mar 31, 2026 | Baker TallyOfficer | — | 110.5K | — |
| Nov 2, 2025 | Syed Tehsin MChief Technology Officer | — | 424K | — |
| Nov 2, 2025 | Baker TallyOfficer | — | 106K | — |
| Sep 1, 2025 | Trigg DonaldChief Executive Officer | Stock Award(Grant) at price 5.25 per share. | 571.4K | $3.00M |
| Jun 1, 2025 | Felt Bruce C. Jr.Director | Stock Award(Grant) at price 4.30 per share. | 46.5K | $200.00K |
| Jun 1, 2025 | Stevens David BDirector | Stock Award(Grant) at price 4.30 per share. | 46.5K | $200.00K |
| Jun 1, 2025 | Zierhoffer Carol JDirector | Stock Award(Grant) at price 4.30 per share. | 46.5K | $200.00K |
| Jun 1, 2025 | Rodriguez SusanDirector | Stock Award(Grant) at price 4.30 per share. | 46.5K | $200.00K |
Buy / hold / sell counts
Veradigm Inc., a healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally. The company offers solutions to healthcare providers, comprising practice management software, AI patient scheduling software, and electronic statements and payments, and payerpath clearinghouse; revenue cycle services and coding services; electronic health records solutions, which include eprescribe with EPCS, EHR software, veradigm EHR, and practice fusion EHR; and patient engagement platform. It also provides solutions to network partners, which comprise API connectivity solutions, such as veradigm connect, veradigm app expo, and diagnostic ordering and resulting network; life sciences, health plans and payers, and providers; and veradigm eprescribe enterprise. In addition, the company offers risk adjustment solutions, such as health equity analytics, risk adjustment analytics, risk mitigator, comprehensive submissions, and utilization analytics; quality analytics, risk adjustment, and quality management; clinical data exchange and coding solutions, including echart courier, echart coder, and echart integration and analytics; clinical data registries for physicians and veradigm payer insights; provider engagement solutions; care gap alerting, gap closure services, and veradigm payerpath solutions. Further, it provides real world data solutions, such as NLP-enriched EHR data solutions, and clinical data registries; real world evidence and real-world evidence analytics platform; and digital health media solutions. Additionally, the company serves physician practices, hospitals, laboratory and radiology centers, urgent care facilities, health IT companies. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023. Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois.
No recent headlines.
TimeframesDown on the monthly, mixed on the daily and weekly.
pulling back under the 21 EMA
pulling back under the 21 EMA
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.8 | 2.9 | -5.1 | 1.1 | 6.4 | 1.8 | -5.7 | 0.0 | 7.1 | -3.7 | +3.1% | ||
| 2025 | -44.0 | -6.6 | -14.5 | -2.5 | 1.2 | 9.3 | 4.3 | 0.0 | -2.0 | 0.0 | 4.2 | -4.0 | −50.8% |
| 2024 | -13.0 | -34.4 | 28.5 | 3.8 | 18.9 | 0.0 | 1.6 | 3.1 | -2.5 | -3.1 | 10.6 | -6.2 | −7.1% |
| 2023 | 1.5 | -7.3 | -21.4 | -4.3 | -5.7 | 7.0 | 7.3 | -1.0 | -1.8 | 0.4 | -13.0 | -8.6 | −40.5% |
| 2022 | 9.6 | -3.8 | 15.7 | -8.3 | -17.3 | -13.2 | 6.7 | 7.5 | -10.4 | -3.5 | 28.8 | -6.9 | −4.4% |
| 2021 | 14.3 | -6.5 | -2.7 | 3.6 | 11.8 | 6.4 | -7.7 | -10.1 | -13.0 | 3.1 | 20.7 | 10.9 | +27.8% |
| 2020 | -12.6 | -12.1 | -6.6 | -7.7 | -2.8 | 7.1 | 32.9 | -0.8 | -8.8 | 23.8 | 35.7 | 5.6 | +47.0% |
| 2019 | 22.3 | -9.1 | -11.0 | 3.5 | -1.4 | 19.5 | -11.4 | -11.8 | 20.9 | -0.4 | -1.5 | -8.9 | +1.9% |
| 2018 | 2.5 | -7.0 | -11.0 | -5.9 | 8.9 | -5.1 | 2.0 | 19.4 | -2.5 | -16.4 | -14.3 | -5.6 | −33.7% |
| 2017 | 14.7 | 4.0 | 4.1 | -5.6 | -4.7 | 11.8 | -3.5 | 6.7 | 8.3 | -5.3 | 6.1 | 1.7 | +42.5% |
| 2016 | -10.4 | -9.1 | 5.5 | 1.4 | 0.7 | -5.9 | 11.2 | -8.6 | 2.0 | -8.8 | -8.6 | -7.0 | −33.6% |
| 2015 | -6.7 | 0.8 | -0.4 | 11.2 | 5.8 | -2.8 | 5.7 | -4.8 | -9.9 | 13.4 | 8.3 | 1.0 | +20.4% |
| 2014 | 7.1 | 12.1 | -2.9 | -15.6 | -3.2 | 8.9 | -0.8 | -7.2 | -9.2 | 2.2 | -12.4 | 6.2 | −17.4% |
| 2013 | 17.6 | 14.7 | 6.9 | 1.8 | 0.1 | -6.6 | 22.2 | -8.0 | 2.3 | -7.0 | 8.0 | 3.5 | +64.1% |
| 2012 | 1.0 | 1.0 | -14.1 | -33.1 | -2.5 | 1.0 | -15.8 | 14.1 | 18.3 | 4.1 | -14.0 | -15.3 | −50.3% |
| 2011 | 9.5 | 1.1 | -1.7 | 2.6 | -6.6 | -3.4 | -6.5 | -1.0 | 0.3 | 6.3 | 1.6 | -2.7 | −1.7% |
| 2010 | -18.6 | 8.7 | 9.4 | 2.9 | -6.6 | -14.4 | 3.7 | -0.2 | 10.9 | 3.4 | -8.1 | 9.8 | −4.7% |
| 2009 | -15.1 | 3.3 | 18.3 | 20.7 | 3.9 | 22.9 | 8.6 | -13.8 | 36.5 | -3.8 | -1.5 | 5.4 | +103.9% |
| 2008 | -23.6 | -28.1 | -3.3 | 8.1 | 11.4 | -0.2 | -2.9 | 19.0 | -13.2 | -47.7 | 18.5 | 28.8 | −48.9% |
| 2007 | 13.4 | -11.5 | -1.0 | -1.3 | -7.1 | 3.7 | -10.7 | -0.6 | 19.5 | 2.5 | -36.1 | 9.8 | −28.0% |